drugset / Trial / NCT05817201

Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy

NCT05817201

Phase 2/3 Unknown 60 enrolled Taizhou Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to explore the therapeutic efficacy of immune checkpoint inhibitors combined with radical radiotherapy in elderly patients with esophageal cancer.

Timeline

Start
2022-07-01
Primary completion
2023-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator S-1 Small molecule 70 mg/m2
Subject Toripalimab Monoclonal antibody 240 mg

Indications